Close Menu

Compugen

This week, Compugen provided details about an informatics platform it is developing internally for identifying protein functional interaction sites as part of its efforts to discover functional monoclonal antibodies in oncology and immunology that can be used as therapeutic candi

NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.

NEW YORK (GenomeWeb News) – Compugen and DiscoveRx today announced a collaboration to commercialize specially designed peptides matched with specific G protein-coupled receptor targets.

NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its third quarter, the same as in the year-ago period.

The company saw a 146 percent increase year over year in its net loss to $2.2 million.

The firm cut its loss on lower marketing and business development costs.

While it didn't need necessarily need the money from the IPO to continue operations, the money raised will allow Rosetta Green to “ramp up more quickly and accelerate the work they are doing,” a Rosetta Genomics official said.

The company's revenues rose sharply for both the quarter and year, but Compugen cautioned that its revenues are subject to substantial fluctuations.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.